荣昌生物(9995.HK):控费成效显著 重症肌无力数据惊艳

第一上海
14 Apr

积极控费亏损缩窄:公司2024 年实现营收17.1 亿元,同比增长58.9%。公司全年毛利率80.0%,同比提升3.5pts。公司Q4 加强了了营销活动,全年销售费用率55.5%。研发费用方面公司对管线进行了调整和重点聚焦,全年研发费用15.4 亿,成功实现16 亿以下的目标,费用率大幅下降至60.2%。得益于有效的控费举措,公司2024 年归母净亏损14.7 亿元,同比小幅缩窄。截止2024 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10